Skip to main content
OpenTrials
Completed

NCT Number: NCT02575885

Nicotine Delivery From Novel Non-Tobacco Electronic System in Smokers

This randomized pilot clinical trial studies nicotine delivery from novel non-tobacco electronic system (ENDS) in smokers. Studying the levels of nicotine delivered by various types and brands of ENDS to the bloodstream, and comparing this to the levels delivered from conventional cigarettes (the participant's own brand) may help provide information about the use of nicotine-containing products that may help inform/reform current tobacco policy, practice, and harm reduction approaches.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

About this study

PRIMARY OBJECTIVES:

I. Determine the levels of nicotine effectively delivered by various types and brands of ENDS to the bloodstream and compare them to levels delivered from conventional cigarettes. (Study 1)

II. Explore the effect of flavorings added to nicotine solution on puffing topography and nicotine delivery and, assess and compare short-term "functional" nicotine effects of the different products by using subjective measures such as relief of craving and withdrawal symptoms. (Study 2)

SECONDARY OBJECTIVES:

I. Determine the amounts of nicotine present in various brands and types of ENDS. (Study 3)

II. Determine nicotine yields in vapors from various types of ENDS under laboratory conditions. (Study 4)

TERTIARY OBJECTIVES:

I. Develop a standardized testing protocol for ENDS that will reflect users' puffing behavior and product characteristics.

II. Develop and validate the analytical method for analysis of nicotine content in the vapor.

III. Propose a standardized puffing regimen for generating vapors for analytical purposes: Such a testing protocol will reflect the puffing behavior observed among ENDS users and should be specific to ENDS type.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I (Study 1): Participants are asked to smoke ad lib a single cigarette of their own brand and provided with a different type of ENDS product at each visit (e-cigarette, disposable e-cigarette, eGo, personal vaporizer, e-cigar, and e-pipe) over 3.5-4 hours at least 7 days apart for 7 weeks. Participants are provided with cartridges of the same amounts of nicotine with regular (tobacco) or menthol flavor according to smoker's preference, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.

ARM II (Study 2): Participants are asked to smoke ad lib a single cigarette of their own brand and provided with the BLU e-cigarette ENDS product with nicotine solution of one of five flavors over 3.5-4 hours at least 7 days apart for 6 weeks. Participants are provided with cartridges of maximum available amounts of nicotine and different flavors at each visit, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy on the basis of medical history
  • Current moderate-to-heavy smoker as determined by:
  • Has smoked >=10 cigarettes per day regularly for the past year (by history) and (>=5 cigarettes per day Study 2 ONLY)
  • Has an expired carbon monoxide (CO) at screening visit of 8 parts per million (ppm) or more (6 ppm or more Study 2 ONLY)
  • Nicotine dependence assessed as > 4 with the Fagerstrom Test for Nicotine Dependence
  • Willingness to abstain from smoking for 8 hours (overnight abstinence) prior to study visits
  • Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion criteria

  • Unstable medical conditions (such as unstable heart disease, uncontrolled hypertension, thyroid disease, diabetes, renal or liver impairment, glaucoma, or prostatic hypertrophy) or psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder, or current regular use of psychiatric medications such as major tranquilizers and antidepressants
  • Pregnancy or lactation (by history) or positive pregnancy test at screening visit
  • Positive urine drug test at screening visit
  • History of serious side effects from nicotine or from any nicotine replacement therapies
  • Alcohol or illicit drug dependence within the past 12 months (by history and urine tests)
  • Concurrent participation in another clinical trial
  • Unable to communicate in English
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study intervention

Treatment and study plan

Electronic Cigarette

Other

Receive different type of ENDS product at each visit

Other names: e-Cigarette, Electronic Nicotine Delivery System

laboratory biomarker analysis

Other

Correlative studies

pharmacological study

Other

Correlative studies

Questionnaire Administration

Other

Ancillary studies

Primary outcomes

  1. Determine Levels of nicotine effectively delivered by various types and brands of ENDS to the bloodstream and compare them to levels delivered from conventional cigarettes

    Time frame: Up to 1 year

    The maximum concentration of nicotine in plasma (Cmax) will be determined for each product.

  2. Levels of nicotine effectively delivered by various types and brands of ENDS to the bloodstream and compare them to levels delivered from conventional cigarettes

    Time frame: Up to 1 year

    Time to maximum concentration (Tmax) will be determined for each product .

  3. Levels of nicotine effectively delivered by various types and brands of ENDS to the bloodstream and compare them to levels delivered from conventional cigarettes

    Time frame: up to 1 year

    Area under the plasma concentration versus time curve (AUC) will be determined for each product.

  4. Changes in withdrawal symptoms

    Time frame: up to 1 year

    Will be measured with Minnesota Withdrawal Scale

  5. Subjective nicotine effect will be analyzed

    Time frame: up to 1 year

    Will be measured with Drug Effect Questionnaire

  6. Changes in feelings and emotions

    Time frame: up to 1 year

    Will be measured with The Positive Negative Affect Scale

Secondary outcomes

  1. Amounts of nicotine present in various brands and types of ENDS (Study 3)

    Time frame: Up to 1 year

    Nicotine content (mean, median, minimum and maximum) will be determined for each product

  2. Nicotine yields in vapors from various types of ENDS under laboratory conditions (Study 4)

    Time frame: Up to 1 year

    Nicotine yield in vapor will be determined for each product.

Other outcomes

  1. maximum concentration of nicotine in plasma (Cmax) (Study 1 and Study 2)

    Time frame: 2 hours post using ENDS product

    Cmax will be analyzed using a repeated measures analysis of variance, including terms for gender , race and order of treatment

  2. The maximum concentration of nicotine in the area under the plasma concentration - time curve from 0 to 90 minutes (AUC)

    Time frame: 2 hours post using ENDS product

    AUC will be analyzed using a repeated measures analysis of variance, including terms for gender, race and order of treatment.

  3. The time to maximum concentration of nicotine in plasma (tmax)

    Time frame: 2 hours post using ENDS product

    tmax will be analyzed using a repeated measures analysis of variance, including terms for gender , race and order of treatment

  4. Estimated puff volume

    Time frame: 2 hours post using ENDS product

    Puff volume as determined with Cress Micro monitors

  5. Estimated puff duration

    Time frame: 2 hours post using ENDS product

    Puff duration as determined with Cress Micro monitors

Sponsors and collaborators

Lead sponsor

Roswell Park Cancer Institute

Other

Collaborators

  • National Cancer Institute (NCI)
  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Nicotine Delivery From Novel Non-tobacco Electronic Systems (ENDS)

Acronym: ENDS

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Oct 15, 2015
Registry last updated
Jun 12, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.